Phosphagenics appoints pharma veteran
By Dylan Bushell-Embling
Tuesday, 08 July, 2008
Tuesday, 08 July, 2008
Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.
Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.
Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.
Ashton also served as CEO for SkyePharma PLC.
Related News
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
